NCT06743477 A Clinical Study of Ultra-transplantation for the Treatment of Major Thalassemia Scheme
| NCT ID | NCT06743477 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hu Peng |
| Condition | Stem Cell Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 5 participants |
| Start Date | 2025-08-29 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 5 participants in total. It began in 2025-08-29 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Yunnan is a high-incidence area of Eastern Mediterranean (thalassemia) in China, and the treatment cost of thalassemia patients is high, hematopoietic stem cell transplantation (HSCT) is the only means to cure thalassemia, but there are problems in donor screening and the risk of complications. Professor Ai Huisheng's team proposed a new concept of hypertransplantation, which does not require pretreatment and has no risk of GVHD, and animal experiments have shown good efficacy. Under the guidance of Professor Ai, the center plans to carry out clinical research on hypertransplantation and explore safe and effective new therapies for thalassemia.
Eligibility Criteria
Patient inclusion criteria : * Diagnosed with severe Mediterranean anemia, with no restrictions on alpha and beta types; * Age between 7-12 years old, male or female not limited; Weight\<40kg * The patient has or does not have HLA matched or semi matched donors, but unconditionally transplants or refuses to undergo blood stem cell transplantation treatment; And patients who unconditionally or refuse to undergo gene therapy for thalassemia; * There are HLA matched or mismatched donors who meet the donor criteria through physical examination; * The patient and their family agree to receive super transplantation treatment and sign a written informed consent form before the transplantation trial. （2） Exclusion criteria for patients: * Psychiatric patients; * Participants in clinical trials of other drugs within the past month; * There are no suitable HLA mismatched donors available. * Other researchers have determined that they are not suitable to participate in this study. （3） Supplier screening criteria: * HLA typing matches the patient's haplotype * KIR configuration * NIMA * DSA negative * Routine physical examination * Genetic screening for carriers of thalassemia, mild or no carriers of thalassemia * Sign the informed consent form.
Contact & Investigator
Yang T Yang, master
PRINCIPAL INVESTIGATOR
The First People's Hospital of Yunnan
Frequently Asked Questions
Who can join the NCT06743477 clinical trial?
This trial is open to participants of all sexes, aged 7 Years or older, up to 12 Years, studying Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06743477 currently recruiting?
Yes, NCT06743477 is actively recruiting participants. Contact the research team at ynanblood@aliyun.com for enrollment information.
Where is the NCT06743477 trial being conducted?
This trial is being conducted at Kunming, China.
Who is sponsoring the NCT06743477 clinical trial?
NCT06743477 is sponsored by Hu Peng. The principal investigator is Yang T Yang, master at The First People's Hospital of Yunnan. The trial plans to enroll 5 participants.